Please login to the form below
oxycodone
This page shows the latest oxycodone news and features for those working in and with pharma, biotech and healthcare.
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. ... Aximris was
Latest news
-
FDA awards another non-opioid pain drug breakthrough status
Meanwhile one company, Purdue Pharma, has become increasingly identified for fuelling the epidemic with its opioid products, especially OxyContin, a timed-release formulation of opioid pain medication oxycodone.
-
Making a list and checking it twice…
And about making it more difficult to distribute fentanyl and oxycodone-based drugs.
-
FDA panel backs Pfizer and Teva abuse-resistant painkillers
The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... Committee members were swayed by the FDA reviewer's report on Troxyca ER however, which concluded that it was
-
FDA approves Adapt Pharma's opioid overdose nasal spray
The dangers come from prescriptions opioids such as morphine, codeine, methadone and oxycodone as well as illicit opioids like heroine and heroin/fentanyl mixes.
-
Grunenthal and AcelRx’s Zalviso approved in EU
is also heating up as additional potential competitors include the fentanyl transdermal system IONSYS developed by Johnson and Johnson and MoxDuo, an orally administered combination of morphine and oxycodone being developed
More from news
Approximately 2 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
The transatlantic opioid crisis
A landmark ruling by a judge in Oklahoma, USA awarded the state record damages of $572m (£468m) from Johnson &Johnson (J&J), the manufacturer of synthetic opioids like oxycodone and fentanyl
-
Pharma deals during November 2013
The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.
-
Pharma deals during October 2012
34. ††QRxPharma / Paladin Labs. Licence. MoxDuo IR, fixed dose morphine and oxycodone for pain (NDA filed).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
